Share chart BELLUS Health Inc.
Extended chart
Simple chart
About
BELLUS Health Inc., клиническая биофармацевтическая компания, разрабатывает терапевтические средства для лечения хронического кашля и других расстройств гиперчувствительности. Его ведущий кандидат на препарат включает BLU-5937, пероральный мелкомолекулярный антагонист рецептора P2X3, который находится в фазе II клинических испытаний для лечения хронического кашля и хронического зуда. BELLUS Health Inc. была основана в 1993 году со штаб-квартирой в Лавале, Канада.
| EBITDA |
-0.0069 |
| EV/EBITDA |
-12.57 |
| IPO date |
2008-12-29 |
| ISIN |
CA07987C2040 |
| Industry |
Biotechnology |
| P/BV |
2.65 |
| P/S |
3824.15 |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Выручка |
2.6E-5 |
| Див.доход ао |
0 |
| Дивиденд ао |
0.0337 |
| Сайт |
http://www.bellushealth.com
|
| Цена ао |
14.74 |
| Число акций ао |
0.11536 млрд |
| Change price per day: |
0% (14.74) |
| Change price per week: |
0% (14.74) |
| Change price per month: |
0% (14.74) |
| Change price per 3 month: |
0% (14.74) |
| Change price per half year: |
0% (14.74) |
| Change price per year: |
0% (14.74) |
| Change price per 3 year: |
+95.49% (7.54) |
| Change price per 5 year: |
+107.9% (7.09) |
| Change price per 10 year: |
0% (14.74) |
| Change price per year to date: |
0% (14.74) |
|
|
Underestimation
| Title |
Value |
Grade |
| P/S |
61933.24 |
1 |
| P/BV |
2.53 |
6 |
| P/E |
0 |
0 |
| EV/EBITDA |
-12.44 |
0 |
| Total: |
|
2.75 |
|
Efficiency
| Title |
Value |
Grade |
| ROA, % |
-21.21 |
0 |
| ROE, % |
-22.28 |
0 |
| Total: |
|
0 |
|
|
|
Dividends
| Title |
Value |
Grade |
| Div yield, % |
0 |
0 |
| DSI |
0.5714 |
5.71 |
| Total: |
|
0.8157 |
|
Debt
| Title |
Value |
Grade |
| Debt/EBITDA |
-0.0179 |
10 |
| Total: |
|
9.6 |
|
Growth impulse
| Title |
Value |
Grade |
| Yield Revenue, % |
-44.44 |
0 |
| Yield Ebitda, % |
232.66 |
10 |
| Yield EPS, % |
16.87 |
3 |
| Total: |
|
6.6 |
|
| Head |
Job title |
Payment |
Year of birth |
| Mr. Roberto Francesco Bellini |
Pres, CEO & Director |
790.35k |
1980 (44 years) |
| Mr. Ramzi Benamar |
Chief Financial Officer |
650.48k |
1973 (51 year) |
| Mr. Daniel Matthews |
Director of Investor Relations & Communications |
N/A |
|
| Mr. Sebastien Roy |
Corp. Sec. |
N/A |
1976 (48 years) |
| Mr. Tony Matzouranis |
Sr. VP of Bus. Devel. |
N/A |
1973 (51 year) |
| Dr. Catherine M. Bonuccelli M.D. |
Chief Medical Officer |
741.66k |
1958 (66 years) |
| Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBA |
Chief Operating Officer |
417.58k |
1959 (65 years) |
| Dr. Denis Garceau |
Chief Scientific Officer |
|
1957 (67 years) |
| Mr. Francois Desjardins C.A., CPA, CPA, CA |
Sr. VP of Fin. |
|
1963 (61 year) |
